AMBER KING: Open Payments
NPI 1316472392 · OAKLAND, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$347 in 14 payments from 8 companies in 2025. Trend: 2023 $275 · 2024 $263 · 2025 $347
Food & beverage: $247Education: $100
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 3 | $149 |
| AstraZeneca Pharmaceuticals LP | 5 | $89 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $21 |
| ABBVIE INC. | 1 | $21 |
| Exact Sciences Corporation | 1 | $18 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $17 |
| Novo Nordisk Inc | 1 | $17 |
| GlaxoSmithKline, LLC. | 1 | $16 |
Products named: FARXIGA, Veozah, JARDIANCE, QULIPTA, AIRSUPRA, Cologuard Collection Kit, Kerendia, Rybelsus.
Industry payments across MD — which companies pay providers there.
